- Email: [email protected]
Recent literature on fibrinolysis
Recent Literature on Fibrinolysis Fernandez MF; Baffle J; Soler R; Marini Diaz M, Fibrinolysis 1995 Jul;9(4):231-6 Up-regulation of PAI- 1 synthesis by insulin and proinsulin in HEP G2 cells but not in endothelial cells. Alessi MC; Anfosso F; Henry M; Peiretti F; Nalbone G; Juhan-Vague I. Fibrinolysis 1995 Jul;9(4):237-42 The effect oftriglyceride infusion on the regulators offibrinolysis. Barrioeanal LA; Mishra V; Tarbit M; Kesteven P; Alberti KCr, Walker M. Fibrinolysis 1995 Jul;9(4):243-6 Plasminogen activation by recombinant tissue plasminogen activator and potentiation by fibrin: a refined kinetic analysis. Willmott N; Gaffney P. Fibrinolysis 1995 Jul;9(4):247-51 Effects of insulin and some vasoconstrictors onthe synthesis and release oft-PA and PAI-1 from cultured human umbilical vein endothelial cells. Seljeflot I; Amesen H; Stoen R; Lyberg T. Fibrinolysis 1995 Jul;9(4):253-8 Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Violi F; Ferro D; Basili S; Saliola M; Quintarelli C; Alessandri C; Cordova C. Gastroenterology 1995 Aug;109(2):531-9 Prognostic value of clotting and fibnnolytic systems in a follow-up of 165 liver cirrhotic patients. CALC Group. Violi F; Ferro D; Basili S; Cimminiello C; Saliola M; Vezza E; Cordova C. Hepatology 1995 Jul;22(1):96-100 The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery. Wedrich A; Menapace R; Muhlbauer-Ries E. Int Ophthalmol 199495;18(5):277-80 Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. Bajzar L; Manuel R; Nesheim ME. J Biol Chem 1995 Jun 16;270(24):14477-84 Growth and fibrinolytic parameters of human umbilical vein endothelial cells seeded onto cardiovascular grafts. Zhang JC; Wojta J; Binder BR. J Thorac Cardiovasc Surg 1995 Jun;109(6): 1059-65 Changes in coagulation and fibrinolytic system after local intraarterial thrombolysis for acute ischemic stroke. Ueda T; Hatakeyama T; Sakaki S; Ohta S; Kumon Y; Uraoka T. Neurol Med Chir (Tokyo) 1995 Mar,35(3):136-43 Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apneapatients. Rangemark C; Hedner JA; Carlson JT; Gleemp Cr, Winthar K. Sleep 1995 Apt;18(3): 18894 Postoperative changes in plasmatissue-type plasminogen activator and type 1 plasminogen activator inhibitor. Aoki K; Nishino N; Baba S; Urano T; Takada A. Surg Today 1994;24(12): 1039-43 [The venous occlusion test in assessing the fibrinolytic activity of the vascular endothelium in lupus nephritis patients]. Test venoznoi okkliuzii v otsenke fibrinoliticheskoi aktivnosti sosudistogo endoteliia u bol'nykh volchanochnym nefritom. Bobkova IN; Poliantseva LR; Tareeva IE; Andreenko GV; Podorol'skaia LV. Ter Arkh 1995;67(4):42-5 Acute dynamic exercise increases fibrinolytic activity. Rankinen T; Vaisanen S; Penttila I; Rauramaa R. Thromb Haemost 1995 Feb;73(2):281-6 Thrombolysis with tissue plasminogen activator (tPA) is temperature dependent. Yenari MA; Palmer JT; Bracci PM; Steinberg GK. Thromb Res 1995 Mar 1;77(5):475-81 [Blood eoagulation/fibrinolytic disorders in diabetic patients]. Gerinnungs-/Fibrinolysestornngenbei Diabetikern. Julius U. Versichernngsmedizin 1995 Apr 1;47(2):60-3 The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel--a new thromboxane synthase inhibitor. Gryglewski RJ; Szczeklik A; Korbut R; Swies J; Musial J; Krzanowski M; Maga P. Wien Klin Wochenschr 1995;107(9):283-9
W; Worowski K. Acta Pol Pharm 1994;51(6):499-504 Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). yon der Mohlen MA; van Deventer SJ; Levi M; van den Ende B; Wedel NI; Nelson BJ; Friedmann N; ten Care JW. Blood 1995 Jun 15;85(12):3437-43 Hybrid peptide containing RGDF (Arg-Gly-Asp-Phe) coupled with the carboxy terminal part of alpha 2-antiplasmin capable of inhibiting platelet aggregation and promoting fibrinolysis. Udvardy M; Schwartzott D; Jackson K; McKee PA. Blood Coagul Fibrinolysis 1995 Feb;6(1): 11-6 Human intraperitoneal fibrinolytic response to elective surgery. Seott-Coombes D; Whawell S; Vipond MN; Thompson J. Br J Surg 1995 Mar;82(3):414-7 Plasminogen activator activity and plasma-coagulum lysis ' measured by use of optimized fibrin gel structure preformed in microtiter plates. Sidelmann J; Jespersen J; Gram J. Clin Chem 1995 Jul;41(7):979-85 Effects of fish oil on plasma fibrinolysis in patients with mild rheumatoid arthritis. Lau CS; McLaren M; Belch JJ. Clin Exp Rheumatol 1995 Jan-Feb;13(1):87-90 Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Biemond BJ; Levi M; Ten Care H; Van der Poll T; Buller HR; Hack CE; Ten Care JW. Clin Sci (Colch) 1995 May;88(5):58794 The effect on fibrinolytic system of blood plasma of Wister rats after feeding them with Coix mixed diet. Check JB; K'Ombut FO. East Afr Med J 1995 Jan;72(1):51-5 Effects of steroid hormones on fibrinolytic system in cultured human endometrial cells. Miyauchi A; Osuga Y; Taketani Y. Endocr J 1995 Feb;42(1):57-62 Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss. Mastroroberto P; Chello M; Zofrea S; Marehese AR. Eur J Cardiothorac Surg 1995;9(3):143-5 Platelet function and fibrinolytic activity during rest and exercise in borderline hypertensive patients. Gleerup G; Vind J; Winther K. Eur J Clin Invest 1995 Apt,25(4):266-70 Influence of hysterectomy on the fibrinolytic activity of plasma of women with intact ovarian function. Schubring C; GrnlichHenn J; Bauer S; Gips H; Muller-Berghaus G. Eur J Obstet Gynecol Reprod Biol 1995 Mar;59(1):39-43 Pharmacokinetie and biochemical properties of human prourokinase variants carryingamino acids substitutions in the epidermal growth factor-like domain. Morita M; Hirose M; Amatsuji Y; Hase S; Ishikawa H; Tamashima H; Asakura E; Ohkubo M; Tanabe T. Fibrinolysis 1995 Jul;9(4):201-7 Thrombolytic properties of pro-urokinase mutants with mutation in the epidermalgrowth factor-like domain. Yano K; Morimoto H; Morita M; Tanabe T. Fibrinolysis 1995 Jul;9(4):209-14 Purification of human plasminogen activator inhibitor (PAI-1) from Escherichia cell and separation of its active and latent forms by hydrophobic interaction chromatography. Kvassman JO; Shore JD. Fibrinolysis 1995 Jul;9(4):215 -21 Binding ofplasminogen to corneal fibroblasts and their extraceUular matrix. Evidence for a receptor in cell membranes. LopezAlemany R; Mirshahi S; Faure JP; Pouliquen Y; Burtin P; Mirshahi M. Fibrinolysis 1995 Jul;9(4):223-9 Markers of haemostatic system activation in 80 patients with deep venous thrombosis submitted to fibrinolytic therapy. Lopez-
Bibliography prepared from MEDLINE by the British Library Medical Information Centre, covering the September to October 1995 files.
B13
W; Worowski K. Acta Pol Pharm 1994;51(6):499-504 Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). yon der Mohlen MA; van Deventer SJ; Levi M; van den Ende B; Wedel NI; Nelson BJ; Friedmann N; ten Care JW. Blood 1995 Jun 15;85(12):3437-43 Hybrid peptide containing RGDF (Arg-Gly-Asp-Phe) coupled with the carboxy terminal part of alpha 2-antiplasmin capable of inhibiting platelet aggregation and promoting fibrinolysis. Udvardy M; Schwartzott D; Jackson K; McKee PA. Blood Coagul Fibrinolysis 1995 Feb;6(1): 11-6 Human intraperitoneal fibrinolytic response to elective surgery. Seott-Coombes D; Whawell S; Vipond MN; Thompson J. Br J Surg 1995 Mar;82(3):414-7 Plasminogen activator activity and plasma-coagulum lysis ' measured by use of optimized fibrin gel structure preformed in microtiter plates. Sidelmann J; Jespersen J; Gram J. Clin Chem 1995 Jul;41(7):979-85 Effects of fish oil on plasma fibrinolysis in patients with mild rheumatoid arthritis. Lau CS; McLaren M; Belch JJ. Clin Exp Rheumatol 1995 Jan-Feb;13(1):87-90 Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Biemond BJ; Levi M; Ten Care H; Van der Poll T; Buller HR; Hack CE; Ten Care JW. Clin Sci (Colch) 1995 May;88(5):58794 The effect on fibrinolytic system of blood plasma of Wister rats after feeding them with Coix mixed diet. Check JB; K'Ombut FO. East Afr Med J 1995 Jan;72(1):51-5 Effects of steroid hormones on fibrinolytic system in cultured human endometrial cells. Miyauchi A; Osuga Y; Taketani Y. Endocr J 1995 Feb;42(1):57-62 Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss. Mastroroberto P; Chello M; Zofrea S; Marehese AR. Eur J Cardiothorac Surg 1995;9(3):143-5 Platelet function and fibrinolytic activity during rest and exercise in borderline hypertensive patients. Gleerup G; Vind J; Winther K. Eur J Clin Invest 1995 Apt,25(4):266-70 Influence of hysterectomy on the fibrinolytic activity of plasma of women with intact ovarian function. Schubring C; GrnlichHenn J; Bauer S; Gips H; Muller-Berghaus G. Eur J Obstet Gynecol Reprod Biol 1995 Mar;59(1):39-43 Pharmacokinetie and biochemical properties of human prourokinase variants carryingamino acids substitutions in the epidermal growth factor-like domain. Morita M; Hirose M; Amatsuji Y; Hase S; Ishikawa H; Tamashima H; Asakura E; Ohkubo M; Tanabe T. Fibrinolysis 1995 Jul;9(4):201-7 Thrombolytic properties of pro-urokinase mutants with mutation in the epidermalgrowth factor-like domain. Yano K; Morimoto H; Morita M; Tanabe T. Fibrinolysis 1995 Jul;9(4):209-14 Purification of human plasminogen activator inhibitor (PAI-1) from Escherichia cell and separation of its active and latent forms by hydrophobic interaction chromatography. Kvassman JO; Shore JD. Fibrinolysis 1995 Jul;9(4):215 -21 Binding ofplasminogen to corneal fibroblasts and their extraceUular matrix. Evidence for a receptor in cell membranes. LopezAlemany R; Mirshahi S; Faure JP; Pouliquen Y; Burtin P; Mirshahi M. Fibrinolysis 1995 Jul;9(4):223-9 Markers of haemostatic system activation in 80 patients with deep venous thrombosis submitted to fibrinolytic therapy. Lopez-
Bibliography prepared from MEDLINE by the British Library Medical Information Centre, covering the September to October 1995 files.
B13